By Vincent Couey, RxGrab founder. Reviewed by Vincent Wesley Couey. Updated .
For years the trade was simple: if you wanted a GLP-1 for weight loss, you injected it. In 2026 that changed. With the first oral GLP-1 pill approved and priced below the shots, "should I take the pill or the injection, and which is cheaper" is suddenly a real decision. Here is the honest cost-and-results comparison, drawing on our dedicated Foundayo cost guide and Zepbound vs Wegovy guide.
This is the headline shift of 2026. For the first time, a brand-name GLP-1 for weight loss is available for cash under $150 a month, and it is the pill. Here is how the self-pay prices line up:
| Drug | Form | Self-pay cost | With insurance |
|---|---|---|---|
| Foundayo (orforglipron) | Daily pill | $149/mo | ~$25/mo |
| Zepbound (tirzepatide) | Weekly injection | $299-$449/mo | Varies by plan |
| Wegovy (semaglutide) | Weekly injection | ~$350/mo | Varies by plan |
All three are sold through manufacturer direct-pay pharmacies (LillyDirect for Foundayo and Zepbound, NovoCare for Wegovy) with home delivery. The gap is real: the pill's $149 self-pay price is less than half the self-pay cost of the injectable brands. Higher dose tiers and individual insurance coverage can shift these numbers, so confirm your exact price with the manufacturer pharmacy before you decide.
For cash-pay patients in 2026, the pill is the least expensive branded GLP-1 for weight loss.THE 2026 SHIFT
Cost favors the pill, but results still favor the shots. In their trials, the injectables produced more average weight loss than the oral pill:
| Drug | Form | Avg weight loss (trial) | Trial |
|---|---|---|---|
| Zepbound (tirzepatide) | Injection | ~20% | SURMOUNT-5 |
| Wegovy (semaglutide) | Injection | ~14% | SURMOUNT-5 |
| Foundayo (orforglipron) | Pill | ~11.2% | ATTAIN-1 |
These figures come from separate trials, not a single head-to-head study, so treat them as approximate ranges rather than an exact ranking. In the pill's ATTAIN-1 trial (about 3,100 adults over 72 weeks), more than half of participants lost at least 10% of body weight. Sources: Eli Lilly, FDA approval, AJMC, and the published trial data.
The pattern is consistent: injectable tirzepatide (Zepbound) is the strongest, injectable semaglutide (Wegovy) is in the middle, and the oral pill is meaningful but lower. That does not make the pill weak, roughly 11% average weight loss is a genuine clinical result. It means the injection buys you additional weight loss at a higher price and the inconvenience of a weekly shot.
A note on other oral options: not every pill is the same. Foundayo (orforglipron) is the convenient one, taken any time with no food or water rules. Oral semaglutide for weight management (an oral form of Wegovy) is also a pill, but it must be taken in the morning on an empty stomach with a small sip of water and a 30-minute wait before eating or drinking. Rybelsus is oral semaglutide approved for type 2 diabetes, not weight loss. So "the pill" in the weight-loss conversation in 2026 mainly means Foundayo.
Map it to what matters most to you:
Yes, in 2026 the branded pill is cheaper. Foundayo (orforglipron) costs about $25/month insured and $149/month self-pay via LillyDirect, undercutting injectable Zepbound (about $299-$449 self-pay) and Wegovy (about $350 self-pay). For cash-pay patients the pill is currently the least expensive branded GLP-1 for weight loss, though dose tiers and coverage can change the math. Confirm your exact price with the manufacturer pharmacy.
The injections lead on maximum weight loss. In separate trials, injectable tirzepatide (Zepbound) reached about 20% and injectable semaglutide (Wegovy) about 14%, while the oral pill orforglipron (Foundayo) reached about 11.2% in ATTAIN-1. These are from different studies, so treat them as approximate. The pill delivers meaningful weight loss with no needles at a lower price; if maximum weight loss is the priority, injectable tirzepatide is strongest.
It depends on your priorities. Choose the pill (Foundayo) for the lowest cost, no needles, and no food, water, or timing rules, if you accept somewhat less average weight loss. Choose the injection (Zepbound or Wegovy) if maximum weight loss matters most and a weekly shot at a higher price is fine. Some people start on one and switch. This is a medical decision, so your prescriber should make the final call based on your health, not just cost.
For weight loss, the main branded pill in 2026 is Foundayo (orforglipron), taken any time with or without food or water. Oral semaglutide (an oral form of Wegovy) is also a pill but must be taken in the morning on an empty stomach with a small sip of water and a 30-minute wait. Rybelsus is oral semaglutide for type 2 diabetes, not weight loss. The injectables (Zepbound, Wegovy, Mounjaro, Ozempic) remain weekly shots.
For many people, yes. The pill still delivers meaningful weight loss (about 11% on average, with more than half of trial participants losing at least 10% of body weight) at a lower price and with no needles. Whether trading some maximum weight loss for cost and convenience is worth it depends on your goals, budget, and health. If you need the largest possible reduction, the injection is worth its higher cost; if price and needles are the barriers keeping you off treatment, an effective $149 pill can be the better real-world choice. Discuss with your prescriber.
We track direct-pay pricing, new approvals, and coverage changes for Foundayo, Zepbound, Wegovy, and the rest.